<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00133627</url>
  </required_header>
  <id_info>
    <org_study_id>CZAD511ACN01</org_study_id>
    <nct_id>NCT00133627</nct_id>
  </id_info>
  <brief_title>Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis</brief_title>
  <official_title>Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Medications available for the treatment of seasonal allergic conjunctivitis include&#xD;
      antihistamines. These medicines block the release of histamine, a substance in the body that&#xD;
      is released when an allergic reaction occurs. Novartis (NVS) has developed an eye drop&#xD;
      formulation of a well tried antihistamine called ketotifen. This study will compare the&#xD;
      efficacy and the tolerability of ketotifen eye drops with emedastine, which is a popular&#xD;
      treatment for seasonal allergic conjunctivitis in China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Actual">229</enrollment>
  <condition>Seasonal Allergic Conjunctivitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketotifen</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 3 years or older.&#xD;
&#xD;
          -  History of seasonal allergic conjunctivitis&#xD;
&#xD;
          -  Presence of bilateral ocular itching/conjunctival hyperaemia (redness) at baseline:&#xD;
&#xD;
               1. at least intensity degree 2 for itching, and&#xD;
&#xD;
               2. at least intensity degree 4 for composite score of itching and conjunctival&#xD;
                  hyperaemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Other systemic/ophthalmic conditions&#xD;
&#xD;
          -  Presence of any form of allergic conjunctivitis other than seasonal allergic&#xD;
             conjunctivitis (e.g. perennial allergic conjunctivitis, vernal keratoconjunctivitis,&#xD;
             atopic keratoconjunctivitis, giant papillary conjunctivitis).&#xD;
&#xD;
          -  Active bacterial or viral conjunctivitis or history of ocular herpes.&#xD;
&#xD;
          -  Presence or history of severe dry eye.&#xD;
&#xD;
        Previous treatments&#xD;
&#xD;
          -  Any systemic or ocular corticosteroids within two (2) weeks prior to randomization.&#xD;
&#xD;
          -  Any systemic or ocular mast cell stabilizers within two (2) weeks prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Any other ophthalmic medication within three (3) days prior to randomization.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun Xinghuai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital of Shanghai Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital of Shanghai Medical University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>August 22, 2005</study_first_submitted>
  <study_first_submitted_qc>August 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2005</study_first_posted>
  <last_update_submitted>November 16, 2011</last_update_submitted>
  <last_update_submitted_qc>November 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergic</keyword>
  <keyword>Conjunctivitis</keyword>
  <keyword>Ketotifen</keyword>
  <keyword>Histamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketotifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

